论文部分内容阅读
目的探讨孟鲁斯特钠联合罗红霉素、沙丁胺醇治疗咳嗽变异性哮喘合并感染患者对炎症因子及肺功能的影响。方法选择2015年7月—2016年11月收治的咳嗽变异性哮喘合并感染患者68例,随机分为观察组与对照组各34例。对照组使用罗红霉素和沙丁胺醇气雾剂,观察组在此基础上加用孟鲁斯特钠,均治疗1周。比较两组治疗前后炎症因子、肺功能水平。计量资料比较采用t检验。P<0.05为差异有统计学意义。结果治疗前,两组炎症因子水平和肺功能相比,差异无统计学意义(P>0.05);治疗后,观察组炎症因子IL-6及TNF-α水平[(6.58±1.35)、(20.71±3.30)ng/ml]均低于对照组[(10.47±2.56)、(36.67±2.64)ng/ml](均P<0.05),肺功能指标FVC、FEV1、FEV1/FVC[(2.91±0.57)L、(2.91±0.57)L、(90.11±8.23)%]均高于对照组[(2.36±0.31)L、(2.01±0.17)L、(2.01±0.17)%](均P<0.05)。结论针对咳嗽变异性哮喘合并感染患者,孟鲁斯特钠联合罗红霉素、沙丁胺醇治疗有利于降低炎症因子水平,改善肺功能,促进患者康复。
Objective To investigate the effect of monastus combined with roxithromycin and salbutamol on inflammatory factors and pulmonary function in patients with cough variant asthma complicated with infection. Methods Sixty-eight patients with cough variant asthma complicated with infection from July 2015 to November 2016 were randomly divided into observation group (34 cases) and control group (34 cases). The control group using roxithromycin and salbutamol aerosol, the observation group on the basis of the use of montelukast sodium, were treated for 1 week. The two groups before and after treatment of inflammatory cytokines, pulmonary function. Measurement data using t test. P <0.05 for the difference was statistically significant. Results Before treatment, there was no significant difference in the levels of inflammatory cytokines between two groups (P> 0.05). After treatment, the levels of inflammatory cytokines IL-6 and TNF-α [(6.58 ± 1.35) and (20.71 ± 3.30 ng / ml] were significantly lower than those in the control group [(10.47 ± 2.56), (36.67 ± 2.64) ng / ml] (all P <0.05) (2.91 ± 0.17) L, (2.01 ± 0.17) L, (2.01 ± 0.17)%, respectively (all P <0.05) . Conclusion For patients with cough variant asthma with infection, montelukast sodium combined with roxithromycin and salbutamol treatment is beneficial to reduce the level of inflammatory cytokines, improve lung function and promote the recovery of patients.